

09/622094

NZ 99 / 00016

PCT NZ99/00016

Intellectual
Property Office



of New Zealand
Te Pou Rāhui Hanga Hou

REC'D 26 APR 1999

WIPO PCT

CERTIFICATE

This certificate is issued in support of an application for Patent registration in a country outside New Zealand pursuant to the Patents Act 1953 and the Regulations thereunder.


I hereby certify that the annexed is a true copy of the Provisional Specification as filed on 13 February 1998 with an application for Letters Patent number 329799 made by Duirs, Graham Francois.

Dated 17 March 1999.

Neville Harris
Commissioner of Patents

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



329799

PATENTS FORM NO. 4

Appln Fee: \$80.00

James & Wells Ref: 14185/19 BE

RECEIVED
Intellectual Property Office
13 FEB 1983
of New Zealand

PATENTS ACT 1953
PROVISIONAL SPECIFICATION

DRUG DELIVERY SYSTEM

I Graham François Duirs, a New Zealand citizen of 17 MacFarlane
 Street, Hamilton, New Zealand

do hereby declare this invention to be described in the following statement:

DRUG DELIVERY SYSTEM

TECHNICAL FIELD

This invention relates to a substance delivery system.

Reference throughout the specification shall be made to the use of the
5 present invention as a drug delivery system for use in animal body cavities,
such as the vagina.

Should be appreciated however that the present invention can be used to
deliver substances other than drugs and can be used in relation to humans
and in other body cavities, for example the rumen, ears and so forth.

10 BACKGROUND ART

Drug delivery systems are used extensively in controlled breeding and
reproductive management. Although considerable research has been
invested in the design of these devices, there are still problems associated
with them.

15 Firstly, these devices are required to be retained within the body cavity for
the slow release of drugs over a period of time. To facilitate this, various
arms and projections have been built into the device which can either
engage with the walls of the body cavity, or make the device wide enough
such that when in the body cavity it cannot naturally exit the animal
20 through the entrance orifice.

Major problems with the provision of such arms or projections is that they
can irritate or even rupture the lining of the body cavity, causing distress
to the animal and providing a site for possible infection.

A major problem with drug delivery devices is that traditionally they have been manufactured with the drug impregnated into the material from which the device is made. Typically, this material is in many instances a matrix of silicone.

- 5 To manufacture devices from drug impregnated silicone is expensive.

A further disadvantage of using a drug impregnated device is that it is very difficult to dispose. For example, the hormones used in reproductive management are required to be disposed in accordance with heavily regulated environmental procedures. As it is always possible that the drug
10 within the silicone matrix had not been fully delivered to the animal when the device is removed, the whole device will have to be disposed as the whole device is the drug delivery system.

It would be desirable if the devices could be reused.

Another problem with the devices is that they have a specific dose rate
15 which cannot be readily changed. Further with these devices, the treatment cannot be changed or customised according to requirements.

In some animals such as cows, the progesterone dose rate for synchronising oestrus is critical to the reproductive cycle. Typically, in the pre-luteal phase the animal will reproduce follicles which are the stage that ovum are
20 produced. Follicle maturation then occurs and the follicle develops into the corpus luteum in the ovary. Fertilisation can then occur.

Therefore healthy follicles are a pre-requisite for conception.

Exogenous progesterone is often delivered to cows to inhibit follicle maturation as a means of synchronising oestrus. When the treatment is
25 removed progesterone levels fall and the animals cycle in a controlled

manner. If however the progesterone blood levels during treatment fall below critical levels oestrus synchronisation may still occur but follicle integrity may be compromised thereby reducing conception rates and fertility. This condition highlights the necessity to maintain adequate
5 progesterone dose using an efficient drug delivery system.

To maintain adequate dose previous drug delivery systems have contained excessively high progesterone dose levels. This has resulted in high residual levels of drug remaining in the device after use which has adverse economic and environmental impacts.

10 What is required then is a drug delivery device that delivers the drug in a sufficient quantity over the treatment period with a minimum of residual drug remaining in the device matrix after treatment to achieve production economies and to avoid adverse environmental impacts caused by disposing used devices in land fills that contain large quantities of hormones.

15 It is an object of the present invention to address the foregoing problems or at least to provide the public with a useful choice.

Further aspects and advantages of the present invention will become apparent from the ensuing description which is given by way of example only.

20 DISCLOSURE OF INVENTION

According to one aspect of the present invention there is provided a substance delivery device,

the device including a substance dispenser with a surface area, independent of the supporting structure of the substance delivery device.

The substance delivery device should now be referred to as a drug delivery device such as an intravaginal release device (IRD).

It should be appreciated however that a device in accordance with the present invention can be adapted for use in other body cavities such as the
5 rumen, the auditory system, the gum area and other body cavities.

It should also be appreciated that the present invention can be used in both humans and animals.

In preferred embodiments, the present invention may be used in the treatment of cows.

10 The applicant has recognised that a dissolution process as a means of drug delivery is very effective provided the drug release process is controlled. The applicant has in his invention concentrated on the principles which aid dissolution, namely the surface area and thinness of the substance dispensers, surface area exposed directly to the body cavity and in some
15 embodiments the holding of drugs in cavities in the dispenser.

In preferred embodiments the substance dispenser is

As a further issue the applicant has also been conscious of providing a ready means by which the drug profile delivered by the substance delivery device can be readily modified. For example, different animal weights
20 require different amounts of drugs.

The substance being delivered may come in a variety of forms. For example, these may be liquid, bullets, powder, gel, and other such forms. However, this list should not be seen to be exhaustive.

In one embodiment, the substance dispenser may be a pod containing vanes. Preferably, the pod may take the form of an obloid. The vanes may be positioned so that they are axially directed through the centre of the sphere and are in contact with the inside of the sphere at their outer edges.

- 5 Configuring the substance dispenser as a pod should not be seen to be limiting, as the principles of the present invention may be applied using a substance dispenser of a different configuration.

For example the substance dispenser may be a substantially cylindrical device containing vanes, or containing a grid, honeycomb or mesh
10 arrangement. The grid, honeycomb or mesh arrangement may also be applied to the pod configuration for equal effectiveness.

In one embodiment, substance dispenser shall now be referred to as a Matrix Delivery Pod (MDP). Reference to the substance delivery device as an MDP should not be seen to be limiting the scope of the present
15 inventions manufacture or use.

In preferred embodiments, the MDP may be used as a temporary attachment to a Main Carrier Body (MCB), or could be applied as a

permanent attachment to a MCB. In a further preferred embodiment the MDP may be a free-standing delivery pod within the body cavity.

- 20 Preferably the MDP may be used as a temporary attachment to a MCB, such as can be found in New Zealand Patent Application No. 328967. Reference to the device in New Zealand Patent No. 328967 should not be seen to be limiting, as the MCB may constitute another form of device while still maintaining the advantages of the MDP.

The matrix delivery pod has a number of advantages, which are discussed in detail further on.

5 The advantage of configuring the substance dispensing device as a pod containing vanes is that the pod has a large surface area, provides increased durability, and provides increased comfort to the animal to which the device is applied.

10 In further preferred embodiments, the MDP may have the capability of having supplementary MDPs attached to an existing MDP. These supplementary MDPs may be of any suitable shape, such as a cylindrical device, a grid arrangement or a honey-comb or mesh arrangement.

However preferably, the supplementary MDP may be a substantially cylindrical device containing vanes extending towards the centre of the cylinder.

15 The above configuration of the supplementary MDP is that this device may be co-operatively attached to the main MDP, with greater co-operation between the two structures, due to the facing edges of the two MDPs being substantially the same configuration.

The advantage of a supplementary MDP as discussed above will be discussed further on.

20 In other embodiments the dispensing means may be in the form of fingers projecting out from the IRD. This embodiment is discussed later.

In preferred embodiments the support structure may be any device that maintains the structural rigidity of the substance delivery device. For example the support structure may be a frame, a system of struts, a

cantilever support, an air cushion support, a hydraulically supported device, or some other means of support.

In preferred embodiments, the substance being delivered may be drugs such as hormone treatment substances. Reference to the substance being
5 delivered shall hereafter be referred to as drugs, however this should not be seen to be limiting the scope of the present invention's manufacture or use, as other substances may be delivered by the present invention without departing from the present invention's scope of manufacture or use.

This should not be seen to be limiting as other drug delivery devices may
10 be used.

For example, the drug delivery device may be a spine (support structure) with fingers or objects extending from the centre of the spine that carry the drug and such fingers or objects.

Alternatively, there may be a central fixture point with radially extending
15 arms or fingers. The substance to be delivered may be coated or impregnated on these spines or fingers. Other embodiments of the present invention may be used without departing from the scope of the present invention.

Preferably, the vanes may be coated or impregnated with the substance to
20 be dispensed. This has a number of advantages.

The increased surface area of the IRD means that a greater rate of substance transfer may be achieved. Furthermore, the relatively thin nature of the vanes means that a substance that is contained within the material the vanes consist of, may diffuse more quickly to the outside

surface of the vane and be transferred to the animal. This means that a greater proportion of the drugs will be dispensed.

The ability to regulate the device surface area to influence dose levels and to regulate the dose profile through matrix thickness enables specific dose formulations to be delivered through design by varying vane sizes and thickness.

Therefore, the problems associated with residual progesterone in the device may be reduced or overcome. Reduced thickness of the vanes coupled with increased surface area creates more efficient drug transfer resulting in reduced residue. No drugs are associated with the support structure or MCB of the IRD.

Therefore, maximum release of drug to specific dose requirements is achieved also providing minimal residue and an ability to modify surface areas and matrix thickness to meet specific treatment needs. With progesterone treatment good synchrony and fertility rates may be achieved using considerably less progesterone and matrix raw material than existing technologies. Drug residue will be considerably less than existing technologies.

In further preferred embodiments, the vanes may be coated with different drugs and different combinations. This has an advantage that a multi drug dosing system may be implemented.

In some embodiments, the vanes may be configured so that they form a cavity within the drug delivery device. This has a number of advantages.

The first advantage is that the cavities provide an increased surface area whereby fluid which is body fluid may interact with the increased surface

area in the cavity, thereby increasing the capacity for the device to dispense the particular drug desired.

Secondly the cavities provide a space whereby additional materials such as further drugs may be stored for release, improving the drug dispensing economy and storage capacity of the drug dispensing device.

A third advantage of the cavities is that a greater number of cavities provides for multi-dose variability within specific cavities, for delivery of various drug delivery profiles. Thus depending on the dosing required, the amount of drug and particular type of drug may be stored in a particular cavity.

The vanes or cavity surface may be covered with a biodegradable surface to rate release additional substance.

By combining various drugs with various vane thicknesses, the consumer may tailor the drug delivery and dosing to match the particular need of the animal. These needs may be in terms of a type of drug required to be dispensed, and the length of time the drug should be dispensed in.

Thus, various drug delivery profiles may be achieved.

In other embodiments, the vanes may not be surrounded by an outer wall and project directly into the body cavity - being directly exposed to the body fluids in which the drugs dissolve.

Thus the most appropriate dose may be selected and applied to each specific treatment, independent of the main carrier body. This may be selected on the basis of different dosing sizes for larger or smaller animals by weight, but other factors such as the age of the animal, and the medical condition of the animal or other conditions may be used.

The present invention may be manufactured from any substance capable of being impregnated or coated with, and then releasing a drug. For example the present invention may be manufactured from plastic, kevlar™, wood, glass, silicone or other substances

- 5 Preferably however, the present invention may be manufactured from plastics material, polymers or elastomers. The advantages this gives are that the plastic is easily manufactured into the desired shape, is cheap to manufacture, and is malleable so as to prevent irritation to the animal when in use.
- 10 The feature of the present invention regarding the supplementary MDP, enables increased control over dose variance. A supplementary dose or a half dose or other dose profiles may be applied by fixing a supplementary MDP to the main carrier body or to the existing MDP.

Thus, more than one substance may be delivered at a time.

- 15 The use of a MDP provides the ability to replenish treatments or applications, and/or apply them for sustained periods by replacing the MDP, or adding a supplementary MDP.

- The MDP design maximises the surface area such that the dose can be enhanced. This is particularly useful when silicone or polymer type
- 20 materials are used in the construction of the MDP for delivering the substances via dissolution processes.

The MDP enables the thickness of the vanes to be modified and varied such that the drug delivery rates can be manipulated to suit the species and dose profiles required.

- 25 An example of the benefits of an MDP application follows.

In the intravaginal delivery of progesterone in cattle, whereby progesterone is impregnated into a silicone matrix requiring a sustained dose of approximately two ng/ml of exogenous progesterone in the blood. If dose levels decline below this, the follicle condition is impaired and the
5 desired conception rates from the treatment are not achieved after removal of the device.

Using the MDP, various forms of drug delivery can be applied and are not limited to polymer-based dissolution systems. For example, the MDP cavities could be loaded with substances using a biodegradable coating to
10 regulate the release.

Alternatively an electronically controlled pump may be inserted in the MDP to release the substance.

In a further preferred embodiment, an electronic thermometer may be inserted into at least one MDP to provide real time of body temperatures.

15 This has an advantage when determining and monitoring an animals bodily functions, which may be used to determine the dose variants or drug delivery profile required.

In preferred embodiments, the substance dispenser is in the form of drug impregnated or gills attached to the MCB. The surface area of the gills can
20 control the amount of drug delivered and the thickness of the gills controls the duration of the dose.

Therefore, the size of the gills can be used to modify the drug profile as required. Preferably, the profile has a fast drop off with little residual drugs as a consequence of applying these novel design concepts.

25 The gills may also be impregnated with different drugs.

In some embodiments, the gills may be of different types, for example, end gills and middle gills, wherein the end gills ensure the middle gills are secured with respect to the MCB.

5 The gills have a central aperture that allows them to be readily pushed onto (or pulled off) a MCB. This allows the number of gills and hence dosage amount to be readily changed. Also, only one MCB can be used for multiple treatments by removing expended gills and replacing them with fresh gills.

10 This leads to significantly less wastage than previous devices and less disposal problems.

Preferably, the gills are made of a soft and pliable silicone. This aids animal comfort and welfare and in insertion and removal of the IRD with respect to body orifices. This allows certain configurations of IRDs to be compressed to a smaller size than more rigid devices.

15 **BRIEF DESCRIPTION OF DRAWINGS**

Further aspects of the present invention will become apparent from the following description which is given by way of example only and with reference to the accompanying drawings in which:

Figure 1 shows various views of a vaned pod embodiment, and

20 Figure 2 shows various views of gills used in one embodiments, and

Figure 3 shows various views of further variation of the pod in Figure 1.

BEST MODES FOR CARRYING OUT THE INVENTION

In the reference to Figure 1 there is shown a plan view of a substance dispenser in the form of a pod generally indicated by arrow 1. The pod includes two half hemispheres (2), supporting vanes (3) and cavities (4).

5 In use, the pod (1) is attached to a support structure (not shown) before being inserted into the vagina of an animal such as a cow. The hemispheres (2) and the supporting vanes (3) may be coated with the drug that is required to be dispensed. The pod (1) may be fixed to an insertion device not shown.

10 The supporting vanes (3) may be used as a storage location for further drugs or other substances that are required to be released.

Each of the vanes (3) may be coated or impregnated with the same or a different substance. Similarly, the cavities (4) may hold additional drugs or substances required to be dispensed.

15 Figure 2 shows individual plates which in combination form gills generally indicated by arrow (5) which can be inserted into a support structure of an IRD.

The end gills (6) can be anchored to the support structure ensuring that the middle gills (7) which may sit loosely on the structure do not fall off.

20 Figure 3 illustrates a variation of the embodiment in Figure 1, without an outer shell allowing the vanes to have direct contact with body fluid.

Consequently, the consumer may design a particular drug delivery profile that is suited to the particular application and needs of the animal. The thickness of the vanes may be varied, to comply with the required dosing



329799

rate and drug delivery profile for the particular drug the vanes are
impregnated or coated with. Similarly, the cavities in Figure 1 may
contain an appropriate amount of the substance to be delivered, to comply
with the particular drug delivery profile required to suit the particular
5 needs of the animal.

Aspects of the present invention have been described by way of example
only and it should be appreciated that modifications and additions may be
made thereto without departing from the scope thereof.

GRAHAM FRANÇOIS DUIRS

by their Attorneys

JAMES & WELLS

RECEIVED
Intellectual Property Office
13 FEB 1993
of New Zealand

Figure 1




Figure 2

